New pill plus chemo shows promise in early AML trial
NCT ID NCT06497062
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new targeted drug called sonrotoclax (taken as a pill) combined with standard chemotherapy in 47 adults newly diagnosed with acute myeloid leukemia (AML). The treatment plan is adjusted based on each patient's genetic risk and response. The goal is to see if this combination is safe and improves remission and survival rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sonrotoclax (a targeted cancer drug taken as a pill)
What this could lead to
If successful, this could offer a more effective treatment option for newly diagnosed acute myeloid leukemia, potentially improving remission rates and survival.
What could go wrong
This is an early-phase (Phase 2) study with only 47 participants, so results may not apply to all patients. The drug may cause side effects or fail to improve outcomes compared to standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China